112 related articles for article (PubMed ID: 557448)
1. Comparative cytogenetic and histologic studies on early malignant transformation in mesothelial tumors of the ovary.
Knoerr-Gaertner H; Schuhmann R; Kraus H; Uebele-Kallhardt B
Hum Genet; 1977 Mar; 35(3):281-97. PubMed ID: 557448
[TBL] [Abstract][Full Text] [Related]
2. Genetic disparity between morphologically benign cysts contiguous to ovarian carcinomas and solitary cystadenomas.
Zheng J; Benedict WF; Xu HJ; Hu SX; Kim TM; Velicescu M; Wan M; Cofer KF; Dubeau L
J Natl Cancer Inst; 1995 Aug; 87(15):1146-53. PubMed ID: 7674319
[TBL] [Abstract][Full Text] [Related]
3. Proliferative serous tumors of the ovary. Histologic features and prognosis.
Katzenstein AL; Mazur MT; Morgan TE; Kao MS
Am J Surg Pathol; 1978 Dec; 2(4):339-55. PubMed ID: 736209
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetics of a cell line derived from an ovarian papillary serous cystadenocarcinoma.
Hill SM; Rodgers CS; Hultén MA; Wilson AP
Cancer Genet Cytogenet; 1984 Aug; 12(4):321-7. PubMed ID: 6744227
[TBL] [Abstract][Full Text] [Related]
5. Frequency of papillary tubal hyperplasia (PTH), salpingoliths and transition from adenoma to borderline ovarian tumors (BOT): A systematic analysis of 74 BOT with different histologic types.
Horn LC; Angermann K; Hentschel B; Einenkel J; Höhn AK
Pathol Res Pract; 2017 Apr; 213(4):305-309. PubMed ID: 28238382
[TBL] [Abstract][Full Text] [Related]
6. Trisomy 12 is a consistent chromosomal aberration in benign ovarian tumors.
Pejovic T; Heim S; Mandahl N; Elmfors B; Flodérus UM; Furgyik S; Helm G; Willén H; Mitelman F
Genes Chromosomes Cancer; 1990 May; 2(1):48-52. PubMed ID: 2177641
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal aberrations in an ovarian cystadenoma.
Benedict WF; Rosen WC; Brown CD; Porter IH
Lancet; 1969 Sep; 2(7621):640. PubMed ID: 4185609
[No Abstract] [Full Text] [Related]
8. Comparative cytogenetic studies of benign, borderline, and malignant epithelial ovarian tumors.
Izutsu T; Kudo T; Shoji T; Nishiya I
J Obstet Gynaecol Res; 1996 Dec; 22(6):541-9. PubMed ID: 9037943
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
10. [Chromosome abnormalities in an ovarian cancer].
Berger R; Lacour J
Pathol Biol (Paris); 1974 Sep; 22(7):603-6. PubMed ID: 4612464
[No Abstract] [Full Text] [Related]
11. Centromere spreading and centromeric aberrations in ovarian tumors.
Zhu D; Ma MS; Zhao RZ; Li MY
Cancer Genet Cytogenet; 1995 Mar; 80(1):63-5. PubMed ID: 7697635
[TBL] [Abstract][Full Text] [Related]
12. Cytogenetic observations on two ovarian carcinomas with double minutes, one with a 6q- marker chromosome.
Bullerdiek J; Bartnitzke S; Kahrs E; Schloot W
Cytobios; 1985; 42(165):15-24. PubMed ID: 3858061
[TBL] [Abstract][Full Text] [Related]
13. Borderline malignant serous tumors of the ovary maintained on extracellular matrix: evidence for clonal evolution and invasive potential.
Crickard K; Marinello MJ; Crickard U; Satchidanand SK; Yoonessi M; Caglar H
Cancer Genet Cytogenet; 1986 Oct; 23(2):135-43. PubMed ID: 3756833
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between malignant transformation of ovarian mucinous cystadenoma and intestinal epithelial metaplasia].
Zhong CQ
Zhonghua Bing Li Xue Za Zhi; 1989 Jun; 18(2):134-6. PubMed ID: 2555075
[TBL] [Abstract][Full Text] [Related]
15. [A serous cystadenoma of the ovary of borderline malignancy with a fifteen-year history. A case report].
Nagata O; Aramaki S; Iino H; Ishikawa S; Yoshida H; Azekami M; Yamaguchi Y; Iwasa T; Matsukuma K; Iwata Y
Gan No Rinsho; 1990 Apr; 36(5):669-73. PubMed ID: 2325270
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal analysis in malignant ovarian tumors.
Sonwalker AA; Grover S
Am J Obstet Gynecol; 1974 Apr; 118(7):961-5. PubMed ID: 4361960
[No Abstract] [Full Text] [Related]
17. A benign serous ovarian cystadenoma studied by chromosome and quantitative DNA analysis.
Wager J; Granberg I; Vass L; Auer G
Acta Cytol; 1977; 21(6):774-6. PubMed ID: 274883
[TBL] [Abstract][Full Text] [Related]
18. ras oncogene product p21 expression and prognosis of human ovarian tumors.
Yaginuma Y; Yamashita K; Kuzumaki N; Fujita M; Shimizu T
Gynecol Oncol; 1992 Jul; 46(1):45-50. PubMed ID: 1634140
[TBL] [Abstract][Full Text] [Related]
19. A chromosome study of three ovarian tumors.
Jenkyn DJ; McCartney AJ
Cancer Genet Cytogenet; 1987 Jun; 26(2):327-37. PubMed ID: 3471312
[TBL] [Abstract][Full Text] [Related]
20. Expression of glucose transporter protein 1 and p63 in serous ovarian tumor.
Cai Y; Zhai JJ; Feng BB; Duan XZ; He XJ
J Obstet Gynaecol Res; 2014 Jul; 40(7):1925-30. PubMed ID: 25056472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
